2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2752

Successfull Evaluation of a Predefined Set of Anatomic Sites in the Pelvis of Patients with Polymyalgia Rheumatica Showing Extracapsular Inflammation as Visualized by Contrast Enhanced Magnetic Resonance Imaging
Abstract Number: 129

Surface Proteins on Exosomes Derived from Plasma of APS Patients Indicate an Altered Immune, Cell Adhesion and Coagulation Profile
Abstract Number: 393

Surfactant Protein D as a Useful Predictor for Mortality in Myositis-associated Interstitial Lung Disease: A Dimorphic Model Based on anti-MDA5 Antibody
Abstract Number: 2194

Surgical and Medical Weight Loss Threshold Dictates Decreases in Knee Osteoarthritis Pain but Not Reductions in Inflammatory Biomarkers
Abstract Number: 1786

Surrogate Pathways of Complement Activation in Novel Polygenic SLE-like Models of Kidney Injury
Abstract Number: 873

Survival After Lung Transplantation in Adults with Primary Systemic Vasculitides: Analysis of the United Network of Organ Sharing (UNOS) Database
Abstract Number: 1114

Survival and Cost of Biologic DMARDs in a Military Medical Center: A Quality Improvement Initiative
Abstract Number: 1674

Survival in ANCA-Associated Vasculitis in a Latin-American Center: 28 Years of Experience
Abstract Number: 2646

Survival of Large Vessel Giant Cell Arteritis in Northern Italy During a 26-year Period : No Correlation with Demographical, Clinical, Laboratory and Imaging Data
Abstract Number: 2669

Survival Trends in Giant Cell Arteritis: A Population-based Cohort Study
Abstract Number: 2001

Survivin Controls the Transcriptional Activity by Changing the Pattern of Histone H3 Marks on Chromatin
Abstract Number: 1115

Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
Abstract Number: 2111

Symptomatic Coccidioidomycosis Infections in Patients on Biologic Therapies
Abstract Number: 2246

Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Abstract Number: 1473

Syndecan-1 Is a Potential Biomarker for Salivary Glandular Function and Disease Activity in Patients with Sjögren’s Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].